Black Diamond Therapeutics, Inc. announced the appointment of Sergey Yurasov, M.D., Ph.D., as Chief Medical Officer. In conjunction with the appointment of Dr. Yurasov, Karsten Witt, M.D., is transitioning from his current role as the Company's Interim Chief Medical Officer to a clinical advisory role. Dr. Yurasov joins Black Diamond Therapeutics from Nuvation Bio, an oncology therapeutics company.

As Chief Medical Officer at Nuvation Bio, Dr. Yurasov was instrumental in the company's successful public offering in February 2021, and spearheaded the company's clinical development strategy in multiple oncology indications for a number of small molecule programs. Prior to Nuvation Bio, Dr. Yurasov was the Chief Medical Officer and Senior Vice President of Clinical Development at Immune Design Corp., an immune-oncology company, which was acquired by Merck in March 2019.